News
Polatuzumab Vedotin in Combination Treatment of Patients with R/R DLBCL
Polatuzumab Vedotin is a conjugate of a cytostatic agent and an antibody against CD79b, a component of the B-lymphocyte receptor typically expressed by diffuse large B-cell lymphoma (DLBCL) cells. In combination with bendamustine and rituximab (pola-BR), this drug is administered in the 3rd and subsequent lines of treatment for relapsed or refractory (R/R) DLBCL. If allogeneic hematopoietic stem cell transplantation (HSCT) is not feasible, patients with R/R DLBCL generally have a very poor prognosis, with limited further treatment options.…
End of Unnecessary Biopsies? Prostate Health Index (PHI) in Detecting Aggressive Carcinoma
The Prostate Health Index (PHI) combines the results of three blood-derived parameters: total PSA…
Prediction of Cancer Aggressiveness: Prostate Health Index (PHI) as a Promising Future Marker
The Prostate Health Index (PHI) is a diagnostic blood test that combines the levels of…
Cardiovascular Benefit of SGLT2 Inhibitors Confirmed
The cardiovascular (CV) benefit of SGLT2 inhibitors in type 2 diabetics, demonstrated by empagliflozin...
Why Do Women in the USA Receive Indicated Statin Therapy Less and in Lower Doses Than Men?
Statin use has been proven to reduce the risk of cardiovascular diseases in both men and women.…
Efficacy and Safety of High Doses of Enoxaparin in Preventing Thromboembolic Disease in Morbidly Obese Patients
Thromboembolic disease is a significant cause of morbidity and mortality in hospitalized patients,…
Prophylaxis of Thromboembolism with Low-Molecular-Weight Heparins in Oncology Patients: Efficacy and Safety of Doses Adjusted According to Anti-Xa Activity
Oncological patients undergoing surgical procedures are observed to have a high risk of…
Evaluation of the m7-FLIPI score in patients with follicular lymphoma revealed a promising predictive biomarker for determining suitable chemotherapy
The authors of a study presented at the December congress of the American Society of Hematology…
Kadcyla in a New Indication – Adjuvant Therapy for Early HER2+ Breast Cancer
In December, the European Commission approved the expansion of the indication for Roche's medicinal…
Comparison of Safety and Efficacy of Oral and Intravenous Administration of Combination NEPA in the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting
Both oral and intravenous administration of a combination of netupitant (a neurokinin 1 receptor…
Conferences
News from the world of medicine
All conferences
Popular this week
- Multiple system atrophy
- Intermittent Fasting May Carry Significant Health Risks
- How Compassion Fatigue Threatens Doctors and Other Healthcare Workers
- Modern approaches enhancing the efficiency of antibiotic therapy in hospital practice
- Tuberous Sclerosis